'
Supriya
Lifescience hosted a conference call on Jan 27, 2025. During the call, the
company was represented by Dr. Satish Wagh, Executive Chairman & WTD; Dr.
Saloni Wagh, Managing Director; and Mr. Krishna Raghunathan, Chief Financial
Officer.
Key takeaways of the call
The company
reported revenue growth of 33% YoY supported by efficient execution across
therapeutic segments.
Focus on niche
and high value products has led to significant improvement in EBITDA margin.
Going forward, management expects strong margin to sustain.
In Q3 FY25, Asia contributed 31% to
total revenue, Europe 40%, LAC 21%, North America 3% and others 5%.
During 9M FY25, Asia contributed 32%
to total revenue, Europe 43%, LAC 17%, North America 4% and others 4%.
In Q3 FY25, in terms of therapy wise
contribution...
Pleaselogin & subscribe to view the full report.
More Reports
|
|